Compare Incyte Corporation (INCY) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ryanair Holdings plc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Ryanair Holdings plc trades at $58.99 (market cap $29.31B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.68% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RYAAY | |
|---|---|---|
Market Cap | $23.11B | $29.31B |
Sector | Health | Industrials |
52-Week High | $118.52 | $73.82 |
52-Week Low | $67.38 | $53.24 |
Enterprise Value | $19.13B | $26.33B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
RYAAY trades at $58.80, down 6.03% amid a bearish technical signal. Recent Q1 2027 earnings missed expectations due to lower fares and higher fuel costs, though the company maintains strong profitability with a 13.98% net margin. Analyst consensus remains positive with 62.5% buy ratings, citing long-term advantages despite near-term headwinds from geopolitical tensions and industry volatility.
The outlook is cautious short-term given earnings pressure and technical weakness, but the strong balance sheet and potential industry consolidation offer recovery potential. Key risks include fuel price volatility and competitive fare pressures, while institutional sentiment suggests the sell-off may be overdone for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
